Myhibbin in Saudi Arabia
How patients in Saudi Arabia access Myhibbin (nintedanib class) via Named Patient Program.
Myhibbin - overview
Myhibbin (nintedanib class) is manufactured by Boehringer Ingelheim (verify) and indicated for prophylaxis of organ rejection in adult and pediatric recipients of allogeneic kidney, heart, or liver transplants. It is an oral suspension, ready-to-use (no reconstitution) approved by the US FDA in 2024 and may be accessible to patients in Saudi Arabia through a Named Patient Program or personal-import pathway.
Access in Saudi Arabia
The Saudi Food and Drug Authority (SFDA) operates a Personal Import / Unregistered Medicine pathway for named patients, typically requiring physician justification and hospital ethics-committee review.
How Reserve Meds coordinates access in Saudi Arabia
- Patient or treating physician submits a request.
- We verify clinical appropriateness and Saudi Arabia-specific eligibility.
- Treating physician in Saudi Arabia issues prescription and clinical justification.
- Country-specific NPP/personal-import forms are prepared and filed.
- We source Myhibbin from a DSCSA-compliant US specialty wholesaler.
- Cold-chain shipment to the patient's physician or hospital pharmacy in Saudi Arabia.
Typical timeline for Saudi Arabia
End-to-end, most requests are completed in 2-6 weeks. Saudi Arabia's tier 1 regulatory maturity typically supports fast processing times.
What patients and physicians in Saudi Arabia ask
- Is the pathway legal in Saudi Arabia? Yes - it operates under Saudi Arabia's established NPP or personal-import framework.
- Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
- What physician credentials do I need? A licensed physician in Saudi Arabia able to issue the prescription and clinical justification.
- What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
- Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.